Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Glofitamab in Combination with R-ICE Chemoimmunotherapy or as Monotherapy in Children and Adolescents with Relapsed/Refractory B-cell non-Hodgkin Lymphoma: Initial Safety and Efficacy Results from the Ongoing iMATRIX-GLO Study

Véronique Minard-Colin, Maitane Andión Catalán, Luciana Vinti, Hyoung Jin Kang, Nora Rahmani, Katia Gamel, Jade Wulff, Saibah Chohan, Raluca Negricea, Beate Wulff, Birgit Burkhardt

Blood (2024) 144 (Supplement 1): 6483.

https://doi.org/10.1182/blood-2024-194331

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) Assessment in Pediatric Patients with Newly Diagnosed High-Risk Classic Hodgkin Lymphoma (cHL): Exploratory Analysis from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 6196.

https://doi.org/10.1182/blood-2024-200309

Published: 2024

Journal Articles

CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review

Luciana Vinti, Jolanda Pianese, Elisa Carraro, Paola Muggeo, Daniela Onofrillo, Irene d'Alba, Elisabetta Schiavello, Raffaella De Santis, Concetta Micalizzi, Veronica Barat, Katia Perruccio, Luca Lo Nigro, Barbara Buldini, Lara Mussolin, Valentina Bertaina, Rita de Vito, Marta Pillon, Franco Locatelli

Blood (2024) 144 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2024-208728

Published: 2024

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2024-199675

Published: 2024

Journal Articles

Somatic and Germline Cohesin Genes Alterations in Pediatric Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2023-189244

Published: 2023

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Auke Beishuizen, Luciana Vinti, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Franca Fagioli, Constantino Sabado Alvarez, Stephane Ducassou, Salvatore Buffardi, Maitane Andión Catalan, Brad Hoppe, Frank Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Stephen Daw

Blood (2023) 142 (Supplement 1): 3063.

https://doi.org/10.1182/blood-2023-187028

Published: 2023

Journal Articles

Brentuximab in Children, Adolescent and Young Adults with Relapsed/Refractory Anaplastic Large Cell Lymphoma

Luciana Vinti, Pietro Merli, Emanuele Agolini, Francesca Stocchi, Barbarella Lucarelli, Katia Girardi, Mattia Algeri, Emilia Boccieri, Mariachiara Lodi, Marco Becilli, Maria Giuseppina Cefalo

Blood (2022) 140 (Supplement 1): 12141–12142.

https://doi.org/10.1182/blood-2022-170118

Published: 2022

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Blood (2021) 138 (Supplement 1): 1231.

https://doi.org/10.1182/blood-2021-145476

Published: 2021

Journal Articles

Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants

Blood (2021) 137 (14): 1980–1984.

https://doi.org/10.1182/blood.2020009032

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134774

Published: 2020

Journal Articles

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Blood (2019) 134 (Supplement_1): 2069.

https://doi.org/10.1182/blood-2019-127969

Published: 2019

Journal Articles

Comparative Analysis of Alpha-Beta T-Cell and B-Cell Depleted (abTCD) HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) Versus Abtcd Haplo-HSCT with T-Cell Add-Back of Rivogenlecleucel Cell [Donor T Cells Transduced with the Inducible Caspase 9 (iC9) Gene Safety Switch] in Children with High-Risk Acute Leukemia (AL) in Remission

Annalisa Ruggeri, MD, Pietro Merli, MD, Mattia Algeri, MD, Marco Zecca, Franca Fagioli, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Arcangelo Prete, MD, Mauro Montanari, MD, Francesca Del Bufalo, MD, Luciana Vinti, MD, Daria Pagliara, MD PhD, Melissa Aldinger, PharmD, Kai Chan, Paul Woodard, Federica Galaverna, MD, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 145.

https://doi.org/10.1182/blood-2019-125366

Published: 2019

Journal Articles

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Luciana Vinti, MD, Luisa Strocchio, MD, Barbara Buldini, MD PhD, Daniela Silvestri, Valentino Conter, MD, Pietro Merli, MD, Carmelo Rizzari, Rosanna Parasole, MD, Maddalena Paganin, PhD, Giuseppe Basso, MD PhD, Marco Zecca, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 2580.

https://doi.org/10.1182/blood-2019-131292

Published: 2019

Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Blood (2019) 134 (Supplement_1): 2629.

https://doi.org/10.1182/blood-2019-122411

Published: 2019

Journal Articles

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Francesca Del Bufalo, MD, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Ignazio Caruana, PhD, Matilde Sinibaldi, PhD, Luciana Vinti, MD, Pietro Merli, MD, Mattia Algeri, MD, Annalisa Ruggeri, MD, Federica Galaverna, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Giuseppina Li Pira, PhD, Giovanna Leone, MD, Valentina Bertaina, PhD, Franca Fassio, PhD, Monica Gunetti, PhD, Stefano Iacovelli, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 1341.

https://doi.org/10.1182/blood-2019-129821

Published: 2019

Journal Articles

CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells

Concetta Quintarelli, PhD, Simona Sivori, PhD, Simona Caruso, PhD, Simona Carlomagno, PhD, Iolanda Boffa, PhDstudent, Domenico Orlando, PhDstudent, Marika Guercio, Biancamaria Cembrola, PhD, Angela Pitisci, Stefano Di Cecca, PhD, Giuseppina Li Pira, PhD, Luciana Vinti, MD, Biagio De Angelis, PhD, Lorenzo Moretta, MD PhD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2018-99-118005

Published: 2018

Journal Articles

Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts

Concetta Quintarelli, PhD, Iolanda Boffa, PhDstudent, Matilde Sinibaldi, Domenico Orlando, PhDstudent, Marika Guercio, Stefano Di Cecca, PhD, Simona Caruso, PhD, Angela Pitisci, Valentina Bertaina, Francesca Del Bufalo, MD, Pietro Merli, MD, Mattia Algeri, MD, Federica Galaverna, MD, Luciana Vinti, MD, Giuseppina Li Pira, PhD, Biagio De Angelis, PhD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2018-99-119413

Published: 2018

Journal Articles

PACSIN2 rs2413739 Polymorphism and Thiopurine Pharmacokinetics: Validation Studies in Pediatric Patients

Gabriele Stocco, PhD, Raffaella Franca, Diego Favretto, Nagua Giurici, Alessandro Ventura, Giuliana Decorti, Luciana Vinti, MD, Antonella Colombini, Erica Brivio, Laura Rachele Bettini, Ilaria Bini, Francesca Sismondi, Alessandra Mandese, Noelia Malusà, Stefano Martelossi, Marco Rabusin

Blood (2017) 130 (Supplement 1): 4999.

https://doi.org/10.1182/blood.V130.Suppl_1.4999.4999

Published: 2017

NARROW

Glofitamab in Combination with R-ICE Chemoimmunotherapy or as Monotherapy in Children and Adolescents with Relapsed/Refractory B-cell non-Hodgkin Lymphoma: Initial Safety and Efficacy Results from the Ongoing iMATRIX-GLO Study

Circulating Tumor DNA (ctDNA) Assessment in Pediatric Patients with Newly Diagnosed High-Risk Classic Hodgkin Lymphoma (cHL): Exploratory Analysis from the Phase 2 Keynote-667 Study

CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Somatic and Germline Cohesin Genes Alterations in Pediatric Acute Lymphoblastic Leukemia

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Brentuximab in Children, Adolescent and Young Adults with Relapsed/Refractory Anaplastic Large Cell Lymphoma

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells

Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts

PACSIN2 rs2413739 Polymorphism and Thiopurine Pharmacokinetics: Validation Studies in Pediatric Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only